Current aspects in pharmacology of modified hemoglobins
Advanced Drug Delivery Reviews, ISSN: 0169-409X, Vol: 40, Issue: 3, Page: 185-198
2000
- 32Citations
- 26Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations32
- Citation Indexes32
- 32
- CrossRef23
- Captures26
- Readers26
- 26
Article Description
Blood substitutes are products that are designed to replace whole blood (or) red blood cells in the field of transfusion medicine. There are two major classes that belong to this new therapeutics: (i) modified hemoglobins and (ii) perfluorocarbons. Modified hemoglobins have made tremendous progress in the past decade and are being considered for a wide variety of conditions like trauma, elective surgery, oxygenation of tumors to make them more sensitive to radiation therapy, stroke etc. Although, these agents are primarily used for oxygen delivery, their pharmacological actions have been significantly important. Several mechanisms are being explored to explain these pharmacological effects. Modified hemoglobins suffer several drawbacks including hypertension, renal toxicity, and pulmonary hypertension that restrict their development. This review deals with the clinical status and pharmacological actions of modified hemoglobins presently in advanced stages of development and some of the newer generation hemoglobin based therapeutics are also discussed.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0169409X99000496; http://dx.doi.org/10.1016/s0169-409x(99)00049-6; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0342980854&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/10837789; https://linkinghub.elsevier.com/retrieve/pii/S0169409X99000496; http://linkinghub.elsevier.com/retrieve/pii/S0169409X99000496; http://api.elsevier.com/content/article/PII:S0169409X99000496?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0169409X99000496?httpAccept=text/plain; http://dx.doi.org/10.1016/s0169-409x%2899%2900049-6; https://dx.doi.org/10.1016/s0169-409x%2899%2900049-6
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know